Marie Morfouace

European Organisation for Research and Treatment of Cancer — Netherlands

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index919citations79works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(24), Glioma Diagnosis and Treatment(14), Cancer Immunotherapy and Biomarkers(13), Protein Degradation and Inhibitors(8), Cancer, Hypoxia, and Metabolism(7)

Publications79 total

Comprehensive characterization of early-stage Non-Small Cell Lung cancers with multi-modal data integration
2025Open Access
Abstract A007: Is liquid biopsy a reliable surrogate for MSI testing? A concordance study using matched tissue and ctDNA-based NGS
Molecular Cancer Therapeutics·2025
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan
Universität Zürich, ZORA·2025Open Access
3028eP Incidental findings of germline variants in cancer susceptibility genes in liquid biopsies
Annals of Oncology·2025
3059eP BRCA genes reversion mutations in liquid biopsies
Annals of Oncology·2025
Multi-modal image analysis for large-scale cancer tissue studies within IMMUcan
Cell Reports Methods·2025· 1 citedOpen Access
Abstract 1177: Tumor-associated macrophages and clinical outcomes to immunotherapy
Cancer Research·2025
Abstract 7470: Extensive genome sequencing on tissue vs large ctDNA panel: what clinical impact?
Cancer Research·2025
European screening platform for EORTC clinical trials in advanced colorectal cancer ‘SPECTAcolor’
ESMO Gastrointestinal Oncology·2025Open Access
Molecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas
2025Open Access
Multi-modal image analysis for large scale cancer tissue studies within IMMUcan
2025· 3 citedOpen Access
1177P FRESH: The Gustave Roussy program to facilitate access to liquid biopsy for precision oncology in France
Annals of Oncology·2024Open Access
115P Gene rearrangements, actionability and access to precision medicine: Results from the ARCAGEN study
Annals of Oncology·2024Open Access
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers
npj Precision Oncology·2024· 16 citedOpen Access
186P Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: An EORTC IMMUcan sub-project
Immuno-Oncology Technology·2023Open Access
1P Integrated data analysis within IMMUcan identifies prognostic features of early NSCLC
Immuno-Oncology Technology·2023Open Access
176P Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study
Immuno-Oncology Technology·2023Open Access
195P IMMUcan: Toward a better understanding of the tumor microenvironment to inform precision oncology approaches
Immuno-Oncology Technology·2023· 1 citedOpen Access
199P Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium
Immuno-Oncology Technology·2023Open Access
179P Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort
Immuno-Oncology Technology·2023Open Access
page 1 of 4Next →

Frequent Co-authors

Martine F. Roussel(14), Anang A. Shelat(11), Henoch S. Hong(11), Robin Liechti(10), Aleksandra Stevovic(9), Sylvie Rusakiewicz(9), Jean‐Yves Blay(6), Benjamin Besse(6), Nils Eling(6), Bernd Bodenmiller(6), Taosheng Chen(5), Yogesh T. Patel(5), Vassilis Golfinopoulos(5), Sabrina Croce(5), Júlio Oliveira(5), Michelle Daniel(5), Jonas Windhager(5), Bruno Palau Fernandez(5), Daniel Schulz(5), Flavia Marzetta(5)